Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions

W. Noranizah, M. A. Siti-Aishah, M. A. Munirah, M. H. Norazlin, Rohaizak Muhammad, I. Naqiyah, N. A. Sharifah, Srijit Das

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. Vascular endothelial growth factor (VEGF) is a leading factor for tumour angiogenesis and p53 protein is the product of a tumor suppressor gene. The main aim of the study was to assess the association of p53 protein with VEGF expression in breast carcinoma. Materials and Methods. This was a retrospective study involving 66 invasive breast carcinomas, 66 normal breast tissues and 55 cases of usual ductal hyperplasia (UDH), obtained from the histopathology records. The paraffin blocks were cut and processed by immunohistochemical technique using a monoclonal VEGF and a monoclonal p53 antibody. Results. VEGF positive staining was detected in 12 (18.2%) of the 66 cases of breast carcinoma and only 1 (1.8%) of UDH cases (p=0.004). Expression of p53 was positive in 33 (50%) of the 66 cases of carcinoma; whereas 8 cases of UDH (14.5%) were p53 protein positive (p<0.001). There was statistically significant associations between p53 expression and tumour size (p=0.018) and lymph node status (p=0.046). The VEGF and p53 expressions were negative in all normal breast tissues analyzed. Ten (83.3%) of 33 invasive carcinoma with p53 protein positive were VEGF positive, whereas 2 of 33 patients did not have p53 expression and were VEGF positive (p=0.011). Conclusion. The expression of p53 in invasive breast carcinoma had a significant correlation with the tumour size and lymph node metastasis. The evaluation of VEGF expression together with p53 protein may aid clinicians in effective management.

Original languageEnglish
Pages (from-to)129-137
Number of pages9
JournalClinica Terapeutica
Volume161
Issue number2
Publication statusPublished - Mar 2010

Fingerprint

Vascular Endothelial Growth Factor A
Breast
Breast Neoplasms
Hyperplasia
Proteins
Lymph Nodes
Carcinoma
Neoplasms
Angiogenesis Inducing Agents
Tumor Suppressor Genes
Paraffin
Retrospective Studies
Monoclonal Antibodies
Staining and Labeling
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Breast carcinoma
  • p53
  • Pathology
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Noranizah, W., Siti-Aishah, M. A., Munirah, M. A., Norazlin, M. H., Muhammad, R., Naqiyah, I., ... Das, S. (2010). Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions. Clinica Terapeutica, 161(2), 129-137.

Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions. / Noranizah, W.; Siti-Aishah, M. A.; Munirah, M. A.; Norazlin, M. H.; Muhammad, Rohaizak; Naqiyah, I.; Sharifah, N. A.; Das, Srijit.

In: Clinica Terapeutica, Vol. 161, No. 2, 03.2010, p. 129-137.

Research output: Contribution to journalArticle

Noranizah, W, Siti-Aishah, MA, Munirah, MA, Norazlin, MH, Muhammad, R, Naqiyah, I, Sharifah, NA & Das, S 2010, 'Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions', Clinica Terapeutica, vol. 161, no. 2, pp. 129-137.
Noranizah W, Siti-Aishah MA, Munirah MA, Norazlin MH, Muhammad R, Naqiyah I et al. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions. Clinica Terapeutica. 2010 Mar;161(2):129-137.
Noranizah, W. ; Siti-Aishah, M. A. ; Munirah, M. A. ; Norazlin, M. H. ; Muhammad, Rohaizak ; Naqiyah, I. ; Sharifah, N. A. ; Das, Srijit. / Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions. In: Clinica Terapeutica. 2010 ; Vol. 161, No. 2. pp. 129-137.
@article{d700d9ea82cb4e389d458c4118c25dd3,
title = "Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions",
abstract = "Objective. Vascular endothelial growth factor (VEGF) is a leading factor for tumour angiogenesis and p53 protein is the product of a tumor suppressor gene. The main aim of the study was to assess the association of p53 protein with VEGF expression in breast carcinoma. Materials and Methods. This was a retrospective study involving 66 invasive breast carcinomas, 66 normal breast tissues and 55 cases of usual ductal hyperplasia (UDH), obtained from the histopathology records. The paraffin blocks were cut and processed by immunohistochemical technique using a monoclonal VEGF and a monoclonal p53 antibody. Results. VEGF positive staining was detected in 12 (18.2{\%}) of the 66 cases of breast carcinoma and only 1 (1.8{\%}) of UDH cases (p=0.004). Expression of p53 was positive in 33 (50{\%}) of the 66 cases of carcinoma; whereas 8 cases of UDH (14.5{\%}) were p53 protein positive (p<0.001). There was statistically significant associations between p53 expression and tumour size (p=0.018) and lymph node status (p=0.046). The VEGF and p53 expressions were negative in all normal breast tissues analyzed. Ten (83.3{\%}) of 33 invasive carcinoma with p53 protein positive were VEGF positive, whereas 2 of 33 patients did not have p53 expression and were VEGF positive (p=0.011). Conclusion. The expression of p53 in invasive breast carcinoma had a significant correlation with the tumour size and lymph node metastasis. The evaluation of VEGF expression together with p53 protein may aid clinicians in effective management.",
keywords = "Angiogenesis, Breast carcinoma, p53, Pathology, Vascular endothelial growth factor (VEGF)",
author = "W. Noranizah and Siti-Aishah, {M. A.} and Munirah, {M. A.} and Norazlin, {M. H.} and Rohaizak Muhammad and I. Naqiyah and Sharifah, {N. A.} and Srijit Das",
year = "2010",
month = "3",
language = "English",
volume = "161",
pages = "129--137",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions

AU - Noranizah, W.

AU - Siti-Aishah, M. A.

AU - Munirah, M. A.

AU - Norazlin, M. H.

AU - Muhammad, Rohaizak

AU - Naqiyah, I.

AU - Sharifah, N. A.

AU - Das, Srijit

PY - 2010/3

Y1 - 2010/3

N2 - Objective. Vascular endothelial growth factor (VEGF) is a leading factor for tumour angiogenesis and p53 protein is the product of a tumor suppressor gene. The main aim of the study was to assess the association of p53 protein with VEGF expression in breast carcinoma. Materials and Methods. This was a retrospective study involving 66 invasive breast carcinomas, 66 normal breast tissues and 55 cases of usual ductal hyperplasia (UDH), obtained from the histopathology records. The paraffin blocks were cut and processed by immunohistochemical technique using a monoclonal VEGF and a monoclonal p53 antibody. Results. VEGF positive staining was detected in 12 (18.2%) of the 66 cases of breast carcinoma and only 1 (1.8%) of UDH cases (p=0.004). Expression of p53 was positive in 33 (50%) of the 66 cases of carcinoma; whereas 8 cases of UDH (14.5%) were p53 protein positive (p<0.001). There was statistically significant associations between p53 expression and tumour size (p=0.018) and lymph node status (p=0.046). The VEGF and p53 expressions were negative in all normal breast tissues analyzed. Ten (83.3%) of 33 invasive carcinoma with p53 protein positive were VEGF positive, whereas 2 of 33 patients did not have p53 expression and were VEGF positive (p=0.011). Conclusion. The expression of p53 in invasive breast carcinoma had a significant correlation with the tumour size and lymph node metastasis. The evaluation of VEGF expression together with p53 protein may aid clinicians in effective management.

AB - Objective. Vascular endothelial growth factor (VEGF) is a leading factor for tumour angiogenesis and p53 protein is the product of a tumor suppressor gene. The main aim of the study was to assess the association of p53 protein with VEGF expression in breast carcinoma. Materials and Methods. This was a retrospective study involving 66 invasive breast carcinomas, 66 normal breast tissues and 55 cases of usual ductal hyperplasia (UDH), obtained from the histopathology records. The paraffin blocks were cut and processed by immunohistochemical technique using a monoclonal VEGF and a monoclonal p53 antibody. Results. VEGF positive staining was detected in 12 (18.2%) of the 66 cases of breast carcinoma and only 1 (1.8%) of UDH cases (p=0.004). Expression of p53 was positive in 33 (50%) of the 66 cases of carcinoma; whereas 8 cases of UDH (14.5%) were p53 protein positive (p<0.001). There was statistically significant associations between p53 expression and tumour size (p=0.018) and lymph node status (p=0.046). The VEGF and p53 expressions were negative in all normal breast tissues analyzed. Ten (83.3%) of 33 invasive carcinoma with p53 protein positive were VEGF positive, whereas 2 of 33 patients did not have p53 expression and were VEGF positive (p=0.011). Conclusion. The expression of p53 in invasive breast carcinoma had a significant correlation with the tumour size and lymph node metastasis. The evaluation of VEGF expression together with p53 protein may aid clinicians in effective management.

KW - Angiogenesis

KW - Breast carcinoma

KW - p53

KW - Pathology

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=77952635850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952635850&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 129

EP - 137

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 2

ER -